Trends in Outcomes of Revascularization for Left Main Coronary Disease or Three- Vessel Disease With the Routine Incorporation of Fractional Flow Reserve in Real Practice Jung-Min Ahn, MD, Sung-Han Yoon, MD, Jae-Hyung Roh, MD, Pil Hyung Lee, MD, Mineok Chang, MD, Hyun Woo Park, MD, Jong- Young Lee, MD, Soo-Jin Kang, MD, Duk-Woo Park, MD, Seung-Whan Lee, MD, Young-Hak Kim, MD, Cheol Whan Lee, MD, Seungbong Han, PhD, Seong-Wook Park, MD, Seung-Jung Park, MD American Journal of Cardiology Volume 116, Issue 8, Pages 1163-1171 (October 2015) DOI: 10.1016/j.amjcard.2015.07.028 Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 1 The rate of FFR during PCI. American Journal of Cardiology 2015 116, 1163-1171DOI: (10.1016/j.amjcard.2015.07.028) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 2 Changes in treatment strategy in all patients (A), left main disease (B), and three vessel disease (C). American Journal of Cardiology 2015 116, 1163-1171DOI: (10.1016/j.amjcard.2015.07.028) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 3 Kaplan-Meier curve for the composite of death, myocardial infarction, or repeat revascularization (A), the composite of death, myocardial infarction, or stroke (B), and repeat revascularization (C) in the CABG and PCI groups before and after routine use of FFR in the crude population. American Journal of Cardiology 2015 116, 1163-1171DOI: (10.1016/j.amjcard.2015.07.028) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 4 Kaplan-Meier curve for the composite of death, myocardial infarction, or repeat revascularization (A), the composite of death, myocardial infarction, or stroke (B), and repeat revascularization (C) in the CABG and PCI groups before and after routine use of FFR in the PS-matched population. American Journal of Cardiology 2015 116, 1163-1171DOI: (10.1016/j.amjcard.2015.07.028) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 5 Kaplan-Meier curve for the composite of death, myocardial infarction, or repeat revascularization (A), the composite of death, myocardial infarction, or stroke (B), and repeat revascularization (C) before and after routine use of FFR in the PS-matched population. American Journal of Cardiology 2015 116, 1163-1171DOI: (10.1016/j.amjcard.2015.07.028) Copyright © 2015 Elsevier Inc. Terms and Conditions